Together, these data strongly support that ASNS is not only necessary for tumor growth but may also serve as an oncogenic driver contributing to worse outcomes in SCLC patients, highlighting its potential as a therapeutic target during SCLC development and progression. The gene discussed is ASNS; the disease is small cell lung carcinoma.